Teva Pharmaceuticals and Sanofi announced positive results in a Phase 2b trial of their drug for ulcerative colitis and Crohn ...

Duvakitug positive phase 2b results demonstrate best-in-class potential in ulcerative colitis and Crohn’s disease Primary endpoints met in ulcerative colitis (UC) and Crohn’s disease (CD), the most ...

Sanofi and Teva Pharmaceuticals, a US affiliate of Teva Pharmaceutical Industries Ltd., today announced that the RELIEVE UCCD phase 2b study met its primary endpoints in patients with ulcerative ...

Israel's Teva Pharmaceutical Industries and French drugmaker Sanofi said a study of a drug to treat ulcerative colitis and ...

Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) and Sanofi SA’s (NASDAQ:SNY) Phase 2b RELIEVE UCCD study met its primary ...

Duvakitug positive phase 2b results demonstrate best-in-class potential in ulcerative colitis and Crohn's disease Primary endpoints met in ulcerative colitis (UC) and Crohn's disease (CD), the most ...

Teva Pharmaceutical (NYSE:TEVA) and Sanofi (NASDAQ:SNY) stocks were rising on Tuesday after the companies announced successful results of a phase 2 study involving the treatment of patients with ...

Every year, more and more Americans are being diagnosed with inflammatory bowel disease. Who’s at risk for IBD, and what are ...

Crohn’s disease may be a lifelong condition, but today, there are an abundance of effective treatments that can help bring relief to your symptoms and reduce your risk of experiencing more serious ...

Sanofi and Teva report positive Phase IIb results for duvakitug in ulcerative colitis and Crohn's disease, meeting primary ...

Understanding current trends in the incidence, prevalence, and distribution of ulcerative colitis can help inform diagnosis and treatment.

The potential for TL1A-targeting duvakitug to impact unmet needs of patients with ulcerative colitis (UC) and Crohn’s disease ...